Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antihypertensive drugs
Biotech
J&J hands back $230M blood pressure drug with approval in sight
J&J is returning the global rights to the near-approval treatment to Idorsia in a deal worth up to $343 million.
Nick Paul Taylor
Sep 6, 2023 6:20am
Mineralys upsizes IPO to raise $192M for race with AstraZeneca
Feb 10, 2023 9:10am
Quantum's high-stakes hypertension phase 3 fails, tanking stock
Oct 28, 2022 8:55am
J&J's $230M blood pressure bet hits phase 3 endpoint
May 23, 2022 8:57am
